tradingkey.logo

Intuitive Surgical Inc

ISRG
查看詳細走勢圖
542.320USD
0.000
收盤 12/15, 16:00美東報價延遲15分鐘
192.47B總市值
70.51本益比TTM

Intuitive Surgical Inc

542.320
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

-4.33%

1月

-1.31%

6月

+5.88%

今年開始到現在

+3.90%

1年

+0.51%

查看詳細走勢圖

TradingKey Intuitive Surgical Inc股票評分

單位: USD 更新時間: 2025-12-12

操作建議

Intuitive Surgical Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名56/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價601.41。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Intuitive Surgical Inc評分

相關信息

行業排名
56 / 208
全市場排名
142 / 4592
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 34 分析師
買入
評級
601.410
目標均價
+6.09%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Intuitive Surgical Inc亮點

亮點風險
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
業績高增長
公司營業收入穩步增長,連續3年增長34.23%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入8.35B美元
估值合理
公司最新PE估值70.52,處於3年歷史合理位
機構減倉
最新機構持股310.67M股,環比減少3.53%
布蘭德斯投資公司持倉
明星投資者布蘭德斯投資公司持倉,最新持倉481.00股

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Intuitive Surgical Inc簡介

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
公司代碼ISRG
公司Intuitive Surgical Inc
CEORosa (David J)
網址https://www.intuitive.com/en-us/about-us/company

常見問題

Intuitive Surgical Inc(ISRG)的當前股價是多少?

Intuitive Surgical Inc(ISRG)的當前股價是 542.320。

Intuitive Surgical Inc 的股票代碼是什麼?

Intuitive Surgical Inc的股票代碼是ISRG。

Intuitive Surgical Inc股票的52週最高點是多少?

Intuitive Surgical Inc股票的52週最高點是616.000。

Intuitive Surgical Inc股票的52週最低點是多少?

Intuitive Surgical Inc股票的52週最低點是425.000。

Intuitive Surgical Inc的市值是多少?

Intuitive Surgical Inc的市值是192.47B。

Intuitive Surgical Inc的淨利潤是多少?

Intuitive Surgical Inc的淨利潤為2.32B。

現在Intuitive Surgical Inc(ISRG)的股票是買入、持有還是賣出?

根據分析師評級,Intuitive Surgical Inc(ISRG)的總體評級為買入,目標價格為601.410。

Intuitive Surgical Inc(ISRG)股票的每股收益(EPS TTM)是多少

Intuitive Surgical Inc(ISRG)股票的每股收益(EPS TTM)是7.691。
KeyAI